Molecular, genetic and neuroimaging mechanisms of relapse recovery in multiple sclerosis: exploring the role of brain-derived neurotrophic factor - LIONHEARTED (moLecular, genetIc and neurOimagiNg mecHanisms of rElApse recovery in multiple sclerosis: exploRing The role of brain-derivED neurotrophic factor)

Klinik für Neurologie, Universitätsklinikum Frankfurt0 个研究点目标入组 200 人开始时间: 2023年1月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Inclusion criteria for the adult MS group: ability to give informed consent; age 18-60 years; relapsing MS; disease duration = 10 years; last relapse and IVMP/plasmapheresis/immunoadsorption > 30 days ago; no DMT or stable on DMT for the last = 6 months.
•Inclusion criteria for the pediatric MS group: parents’ ability to give informed consent; age 6-17 years; relapsing MS; disease duration = 15 years; last relapse and IVMP/plasmapheresis/immunoadsorption > 30 days ago; no DMT or stable on DMT for the last 6 months.

•Exclusion criteria for the adult MS group: no ability to give informed consent, age < 18 or > 60 years; progressive MS with no relapses; disease duration > 10 years; last relapse and IVMP/plasmapheresis/immunoadsorption = 30 days ago; DMT initiation or not stable on DMT in the last < 6 months.
•Exclusion criteria for the pediatric MS group will be: missing ability of the parents to give informed consent, age < 6 or > 18 years; progressive MS with no relapses; disease duration > 15 years; last relapse and IVMP/plasmapheresis/immunoadsorption = 30 days ago; DMT initiation or not stable on DMT in the last 6 months.

发起方

Klinik für Neurologie, Universitätsklinikum Frankfurt